Source: Beximco Pharmaceuticals Ltd. (BXPHARMA) | FY 2022-23 | Page 143

# AUDITED FINANCIALS

**Reporting Period:** July 2022- June 2023  
**Reporting Currency & Multiplier:** BDT (Amount in Taka) | **Scale Multiplier:** 1

### ii. NPL

| Particulars | July 2022- June 2023 | July 2021- June 2022 |
| --- | --- | --- |
| Property, Plant & Equipment ( Difference in book value & Tax base) | 417,006,176 | 445,608,322 |
| Deferred liability (Gratuity) | (193,019,251) | (173,210,822) |
| Provision for Bad Debts | (2,991,744) | (2,460,877) |
| Temporary Difference | 220,995,181 | 269,936,623 |
| Tax rate | 30.0% | 30.0% |
| Deferred Tax Liability | 66,298,554 | 80,980,987 |
| Deferred tax on revaluation surplus | - | 28,647,841 |
| Deferred tax liabilities at end of the year | 66,298,554 | 109,628,828 |
| Deferred tax liabilities at beginning of the year | 109,628,828 | 117,591,532 |
| Transferred to revaluation reserve | (28,647,841) | - |
| Deferred Tax charged to profit or Loss and Other Comprehensive Income | (14,682,433) | (7,962,704) |

### iii.SPP

| Particulars | July 2022- June 2023 | July 2021- June 2022 |
| --- | --- | --- |
| Property, Plant & Equipment ( Difference in book value & Tax base) | 195,693,431 | 206,672,792 |
| Deferred Liability (Gratuity & Pension) | (128,225,951) | (123,652,254) |
| Provision for Bad Debts & Allowance for Inventory | - | (141,975,425) |
| Carried forward loss | (272,965,958) | (263,373,215) |
| Temporary difference | (205,498,478) | (322,328,102) |
| Tax rate | 27.5% | 27.5% |
| Deferred Tax Liability/(Asset) at end of the year | (56,512,081) | (88,640,228) |
| Deferred Tax Liability/(Asset) at beginning of the year | (88,640,228) | (37,074,071) |
| Deferred tax charged to profit or loss and other comprehensive income | 32,128,147 | (51,566,157) |
| Total (BPL, NPL &SPP) | 75,701,600 | 497,136,316 |

### 31. Other Comprehensive Income - Unrealized Gain/(Loss)

| Particulars | July 2022- June 2023 | July 2021- June 2022 |
| --- | --- | --- |
| Fair Value Gain/(Loss) on Investment in Listed Shares | (2,383,527) | 6,764,517 |
| [Total Unrealized Gain/(Loss)] | (2,383,527) | 6,764,517 |

### 32. Earnings Per Share (EPS)

| Particulars | July 2022- June 2023 | July 2021- June 2022 |
| --- | --- | --- |
| (a) Earnings attributable to the Owners of the Company | 4,614,066,147 | 5,123,136,712 |
| (b) Weighted average number of Shares outstanding during the year | 446,112,089 | 446,112,089 |
| Earnings Per Share (EPS) | 10.34 | 11.48 |